DNLI — Denali Therapeutics Inc. Dilution Risk Tracker

Denali Therapeutics Inc. (DNLI) has a DilutionScore of 27/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

DilutionWatch's EDGAR monitoring for DNLI shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for DNLI in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for DNLI alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.